{"eventGroups":[{"deathsNumAffected":30,"deathsNumAtRisk":55,"description":"Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.\n\nbusulfan: Given IV\n\ncyclophosphamide: Given IV","id":"EG000","otherNumAffected":25,"otherNumAtRisk":55,"seriousNumAffected":11,"seriousNumAtRisk":55,"title":"BuCy"},{"deathsNumAffected":36,"deathsNumAtRisk":69,"description":"Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.\n\ncyclophosphamide: Given IV\n\ntotal-body irradiation: Given twice daily for 3 days","id":"EG001","otherNumAffected":35,"otherNumAtRisk":69,"seriousNumAffected":10,"seriousNumAtRisk":69,"title":"CyTBI"},{"deathsNumAffected":150,"deathsNumAtRisk":199,"description":"Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.\n\nfludarabine phosphate: Given IV\n\nmelphalan: Given IV","id":"EG002","otherNumAffected":100,"otherNumAtRisk":199,"seriousNumAffected":62,"seriousNumAtRisk":199,"title":"FluMel"},{"deathsNumAffected":19,"deathsNumAtRisk":23,"description":"Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.\n\ncyclophosphamide: Given IV\n\netoposide: Given IV\n\ntotal-body irradiation: Given twice daily for 3 days","id":"EG003","otherNumAffected":6,"otherNumAtRisk":23,"seriousNumAffected":6,"seriousNumAtRisk":23,"title":"VpCyTBI"},{"deathsNumAffected":9,"deathsNumAtRisk":15,"description":"Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1. OR Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3. OR Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4. OR Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2. OR Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.","id":"EG004","otherNumAffected":9,"otherNumAtRisk":15,"seriousNumAffected":4,"seriousNumAtRisk":15,"title":"Other"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"overall grade II to IV acute graft versus host disease","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"Glucksberg criteria","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":55,"numEvents":25},{"groupId":"EG001","numAffected":35,"numAtRisk":69,"numEvents":35},{"groupId":"EG002","numAffected":100,"numAtRisk":199,"numEvents":100},{"groupId":"EG003","numAffected":6,"numAtRisk":23,"numEvents":6},{"groupId":"EG004","numAffected":9,"numAtRisk":15,"numEvents":9}],"term":"acute graft-versus-host disease"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"death due to transplant related causes before 1 year after BMT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":55,"numEvents":11},{"groupId":"EG001","numAffected":10,"numAtRisk":69,"numEvents":10},{"groupId":"EG002","numAffected":62,"numAtRisk":199,"numEvents":62},{"groupId":"EG003","numAffected":6,"numAtRisk":23,"numEvents":6},{"groupId":"EG004","numAffected":4,"numAtRisk":15,"numEvents":4}],"term":"1 yr TRM"}],"timeFrame":"1 year"}